Everything below concerns CJC-1295. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-11-01. Numbers and descriptions here follow the published literature rather than marketing material.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
| Property | Value | Notes |
|---|---|---|
| Molecular weight, DAC form | About 3647 Da | Varies with salt form |
| Molecular weight, non-DAC form | About 3358 Da | MOD GRF(1-29) |
| Solubility class | Water soluble | Also dissolves in polar solvents |
| Reported half-life, DAC form | About five to eight days | Values from human studies |
| Common synonyms | CJC-1295; MOD GRF(1-29) | Name depends on variant |
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
Purity is most often assessed by reversed-phase high-performance liquid chromatography, reported as a percentage of total peak area. Identity is confirmed by mass spectrometry, which yields a molecular ion consistent with the expected sequence. Amino acid analysis and peptide mapping provide additional characterization. Reported purity values are method-dependent, so figures from different laboratories are not always directly comparable without details of column, gradient, and detection wavelength.
Peptide degradation proceeds mainly through hydrolysis, oxidation of methionine, and deamidation of asparagine or glutamine residues. The maleimide group on the albumin-binding variant can also react with thiols or hydrolyze in aqueous media. Because these pathways accelerate with temperature and pH extremes, handling conditions strongly influence measured stability. Stability data in the public literature are limited and often generated under differing conditions, so general statements about shelf life should be read as approximate.
== Structure and reactivity == Of the halobenzoquinones, DCBQ is the most commonly detected in drinking waters, up to 275 ng/L, and in chlorinated swimming pools, up to 299 ng/L. DCBQ can undergo hydrolysis, and its main hydrolysis product is DCBQ-OH. The transformation of DCBQ is much quicker in cell tissues than in water. The half-life of DCBQ is ~7h in water compared to ~1h in cell cultures, and is thus more reactive in cell tissues. In the human body, DCBQs can produce reactive oxidative species (ROS) at certain doses, causing mitochondrial dysfunction by reducing the mitochondrial membrane potential, and could promote the mitochondrial apoptosis pathway. DCBQ causes oxidative stress. DCBQ induced a concentration-dependent decrease in cell viability. It has also been found that DCBQ might cause nuclear DNA damage.
In June 2022, following the U.S. Supreme Court's ruling in Dobbs v. Jackson Women's Health Organization, Moore said that he would support an amendment to the Maryland Constitution to enshrine abortion access. He also pledged to release $3.5 million in funding for the Abortion Care Access Act, a bill passed in the 2022 legislative session that would expand the types of medical professionals who can perform abortions in Maryland, on his first day in office. On January 19, 2023, Moore signed his first executive order releasing $3.5 million in funding for training healthcare providers in abortion care under the Abortion Care Access Act. In May 2023, he signed into law a pair of bills aimed at protecting patients seeking an abortion and increase access to abortion medication, and a bill that would create a 2024 referendum on codifying the right to abortion access into the Maryland Constitution. Question 1 passed with more than three times as many voters voting in favor of it than against it. In April 2023, after a federal court ruling in FDA v. Alliance for Hippocratic Medicine repealed the Food and Drug Administration's approval of mifepristone, Moore said the state would begin stockpiling enough of the abortion pill to last two and a half years. In June 2023, he voted to approve $1.3 million toward purchasing 30,000 doses of mifepristone and 5,000 doses of misoprostol. In February 2024, Moore criticized the Alabama Supreme Court's ruling in LePage v. Center for Reproductive Medicine, which held that frozen embryos had the same rights as children, calling it "out of step".
Maggot therapy improves healing in chronic ulcers. In diabetic foot ulcers there is tentative evidence of benefit. A Cochrane review of methods for the debridement of venous leg ulcers found maggot therapy to be broadly as effective as most other methods, but the study also noted that the quality of data was poor. In 2003, the United States Food and Drug Administration (FDA) cleared maggots from the common green bottle fly for use as a "medical device" in the US for the purpose of treatment of:
=== Polysaccharides === Longer than disaccharides are oligosaccharides and polysaccharides. Cellulose and chitin are polymers, often crystalline, found in diverse plants and insects, respectively. Cellulose cannot be digested directly by animals. Starch is an amorphous polymer of glucose that is found in many plants and is widely used in the sugar industry.
=== June === 7 June – The UK Health Security Agency issues a heat health alert for parts of England during the upcoming weekend, when temperatures are expected to reach 30 °C. Woking Borough Council imposes emergency spending restrictions on itself because of a £2bn debt. 8 June – The UK Health Security Agency upgrades the heat health warning for the upcoming warm weather to an amber alert. Henderson Hall in Newcastle is destroyed by a large fire. 9 June – The Independent Office for Police Conduct (IOPC) launches an investigation into the death of a 15-year-old boy whose e-scooter crashed into an ambulance in Salford the previous day, and shortly after he was followed by officers from Greater Manchester Police. Three people, including two students, are described as being in hospital following an assault at the privately run Blundell's School in Tiverton, Devon. A local teenager has been arrested. 10 June – A 16-year-old youth is charged with two counts of attempted murder and one of grievous bodily harm following the previous day's incident at Blundell's School. 11 June – Eight teenagers – six boys and two girls – are arrested following the fatal stabbing of a 16-year-old male youth at a house party in Bath, Somerset the previous evening. 13 June – Three people are killed in attacks across Nottingham City Centre. 21 June – A man is arrested after two people are stabbed at London's Central Middlesex Hospital. He is subsequently charged over the incident. 23 June – Junior doctors in England announce a five-day strike from 7am on 13 July, their longest so far.
Sources: en.wikipedia.org
=== Magnetic plasmon resonance === Recently, there has been an interest in magnetic surface plasmons. These require materials with large negative magnetic permeability, a property that has only recently been made available with the construction of metamaterials.
The Rhodesian Front (RF) was a white supremacist political party in Southern Rhodesia, and, subsequently, the independent Rhodesia. Formed in March 1962 by white Rhodesians opposed to decolonisation and majority rule, it won that December's general election and subsequently spearheaded the country's Unilateral Declaration of Independence (UDI) from the Federation of Rhodesia and Nyasaland in 1965, remaining the ruling party and upholding white minority rule through the majority of the Bush War until 1979. Initially led by Winston Field, the party was led through most of its lifetime by co-founder Ian Smith. Following the end of the Bush War and the country's reconstitution as Zimbabwe, it changed its name to the Republican Front in 1981.
Heart tissue, like all cells in the body, needs to be supplied with oxygen, nutrients and a way of removing metabolic wastes. This is achieved by the coronary circulation, which includes arteries, veins, and lymphatic vessels. Blood flow through the coronary vessels occurs in peaks and troughs relating to the heart muscle's relaxation or contraction. Heart tissue receives blood from two arteries which arise just above the aortic valve. These are the left main coronary artery and the right coronary artery. The left main coronary artery splits shortly after leaving the aorta into two vessels, the left anterior descending and the left circumflex artery. The left anterior descending artery supplies heart tissue and the front, outer side, and septum of the left ventricle. It does this by branching into smaller arteries—diagonal and septal branches. The left circumflex supplies the back and underneath of the left ventricle. The right coronary artery supplies the right atrium, right ventricle, and lower posterior sections of the left ventricle. The right coronary artery also supplies blood to the atrioventricular node (in about 90% of people) and the sinoatrial node (in about 60% of people). The right coronary artery runs in a groove at the back of the heart and the left anterior descending artery runs in a groove at the front. There is significant variation between people in the anatomy of the arteries that supply the heart. The arteries divide at their furthest reaches into smaller branches that join at the edges of each arterial distribution.
Most pharmaceuticals are small molecules - they are equivalent in the literature, although some drugs can be proteins (e.g., insulin and other biologic medical products). With the exception of therapeutic antibodies, many proteins are degraded if administered orally and most often cannot cross cell membranes. Small molecules are more likely to be absorbed, although some of them are only absorbed after oral administration if given as prodrugs. One advantage that small-molecule drugs (SMDs) have over "large-molecule" biologics is that many small molecules can be taken orally whereas biologics generally require injection or another parenteral administration. Small molecule drugs are also typically simpler to manufacture and cheaper for the purchaser. A downside is that not all targets are amenable to modification with small-molecule drugs; bacteria and cancers are often resistant to their effects.
Sources: en.wikipedia.org
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.
The DAC form carries a maleimide group that binds albumin and extends circulation time. The non-DAC form lacks this group and clears much faster. Both share the same receptor-binding core.
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Activation raises cyclic AMP and promotes growth hormone release. Normal feedback pathways remain part of the response.
No. It is a laboratory-synthesized analog built on a fragment of the natural hormone. The natural peptide is shorter-lived and lacks the stabilizing substitutions found in the synthetic version.